Elahe Elhami is currently a Pharma D student at Visveswarapura Institute of Pharmaceutical Sciences. Her area of interest is Basic and Applied Research on Cancer.
Background: Foot infections are a common and serious problem in persons with diabetes. Diabetic foot infections (DFIs) typically begin in a wound, most often a neuropathic ulceration. While all wounds are colonized with microorganisms, the presence of infection is defined by ≥2 classic findings of inflammation or purulence. Infections are then classified into mild (superficial and limited in size and depth), moderate (deeper or more extensive), or severe. Uninfected wounds do not require antibiotic therapy, infected wounds do. Empiric antibiotic regimens must be based on available clinical and epidemiologic data, but definitive therapy should be based on cultures of infected tissue. Objective of the study is to investigate the antimicrobial susceptibility pattern of microbes in DFIs. Inclusion criteria: All diabetic patients admitted to surgery unit with foot ulcer. Exclusion criteria: All patients referred from other unit like medicine or orthopaedics or any other speciality will be excluded. Methodology: We used the patient database to conduct a retrospective observational study of hospitalized patients with diabetic foot infections. Patient record system, which contains patient demographics, diagnoses, diagnostic studies, treatments received and patient outcomes. With this information it is possible to examine the antibiotic regimens of large numbers of diabetic patients with foot infections
Naini Bhadri is pursuing her PhD in Pharmacology from Rajiv Gandhi University of Health Sciences Bangalore (Karnataka). She is a Senior Research Fellow of Indian Council of Medical Research, New Delhi. She has presented research posters in many National and International conferences.
The study was conducted to investigate the neuroprotective potential of allantoin against biochemical, behavioural and electrophysiological deficit in streptozotocin (STZ) induced peripheral neuropathy in diabetic rat. Oral administration of allantoin (100 & 200 mg/kg; per oral) began on the confirmation of diabetes after 72 hours of STZ treatment and was continued for 8 weeks in Wistar albino rats. Determination of body weight and behavioural tests were performed subsequently in every two week during allantoin treatment period. In addition sciatic nerve conduction velocity studies and biochemical parameters of nerve homogenate and serum were performed. In vitro antioxidant activity and AGE (advanced glycation end product) inhibitory assay of allantoin were also performed. Animals treated with allantoin showed a significant improvement in body weight and reduction in serum blood glucose levels as compared to vehicle-treated diabetic rats. Moreover, significant improvement was noted in hyperalgesia, grip strength muscle co-ordination and nerve conduction velocity in allantoin treated diabetic rats. In sciatic nerve there was a significant increase in MDA level and poor antioxidant levels were observed. Reduction in MDA level and NO was determined nevertheless increase in the antioxidant level was perceived in allantoin treated group. Allantoin treatment shows efficacy for preventing diabetic deterioration as seen by improvement in biochemical, behavioural and electrophysiological deficit. The neuroprotective effect of allantoin could be attributed to its anti-hyperglycemic, AGE inhibitory activity and reduction in oxidative and nitrosative stress.